Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 3;148(9):3032-3033.
doi: 10.1093/brain/awaf281.

Plasma biomarker profiles in ageing: decoding neurodegeneration in vivo

Niklas Mattsson-Carlgren  1   2   3
Affiliations
Editorial

Plasma biomarker profiles in ageing: decoding neurodegeneration in vivo

Niklas Mattsson-Carlgren. Brain. .

Abstract

This scientific commentary refers to ‘Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults’ by Yu et al. (https://doi.org/10.1093/brain/awaf211).

PubMed Disclaimer

Conflict of interest statement

N.M.-C. has received consultancy/speaker fees from Biogen, Eli Lilly, Owkin and Merck.

Figures

Figure 1
Figure 1
Linking plasma biomarkers to neuropathological features. Four plasma biomarkers were assessed and used in a data-driven fashion to define three groups of participants. These groups were next characterized according to their expression of different neuropathologies. Profile 2 was enriched for Alzheimer’s disease (AD), cerebral amyloid angiopathy (CAA) and α-synuclein-related features, while Profile 3 was enriched for vascular features. There was not a complete overlap between biomarker profiles and neuropathological features, and some neuropathologies did not differ at all between biomarker profiles. Aβ = amyloid-β.
See this image and copyright information in PMC

Comment on

References

    1. Khalafi M, Dartora WJ, McIntire LBJ, et al. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer’s disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis. Alzheimers Dement. 2025;21:e14458. - PMC - PubMed
    1. US Food and Drug Administration . FDA Clears first blood test used in diagnosing Alzheimer’s disease. FDA; 2025. Accessed 28 May 2025. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blo...
    1. Yu L, Du L, Wang T, et al. Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults. Brain. 2025;148:3340–3349. - PMC - PubMed
    1. Mattsson-Carlgren N, Grinberg LT, Boxer A, et al. Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2022;98:e1137–e1150. - PMC - PubMed
    1. Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13:e14022. - PMC - PubMed